🔗 Share this article

Ex-government leader Rishi Sunak has strengthened his campaign for a focused testing initiative for prostate gland cancer.

During a recently conducted discussion, he stated being "convinced of the immediate need" of introducing such a system that would be economical, feasible and "save numerous lives".

His comments emerge as the British Screening Authority reconsiders its decision from the previous five-year period against recommending routine screening.

Media reports indicate the authority may uphold its present viewpoint.

Athlete Contributes Support to Movement

Champion athlete Sir Chris Hoy, who has advanced prostate gland cancer, supports men under 50 to be screened.

He suggests decreasing the minimum age for requesting a prostate-specific antigen laboratory test.

Currently, it is not standard practice to healthy individuals who are below fifty.

The PSA test is debated nevertheless. Levels can increase for reasons apart from cancer, such as bacterial issues, leading to false positives.

Skeptics contend this can cause unnecessary treatment and adverse effects.

Targeted Testing Proposal

The proposed examination system would target individuals in the 45-69 age bracket with a genetic predisposition of prostate gland cancer and black men, who face double the risk.

This group encompasses around over a million males in the UK.

Organization calculations suggest the system would require £25 million annually - or about eighteen pounds per participant - comparable to intestinal and breast screening.

The assumption envisions twenty percent of qualified individuals would be invited each year, with a 72% response rate.

Clinical procedures (imaging and tissue samples) would need to expand by twenty-three percent, with only a moderate growth in medical workforce, based on the study.

Medical Professionals Response

Various healthcare professionals are doubtful about the effectiveness of examination.

They assert there is still a possibility that patients will be treated for the cancer when it is potentially overtreated and will then have to experience complications such as incontinence and impotence.

One prominent urological professional remarked that "The problem is we can often identify abnormalities that doesn't need to be treated and we potentially create harm...and my apprehension at the moment is that harm to benefit ratio needs adjustment."

Patient Experiences

Patient voices are also affecting the discussion.

A particular case concerns a sixty-six year old who, after asking for a PSA test, was diagnosed with the cancer at the time of fifty-nine and was advised it had spread to his hip region.

He has since undergone chemo treatment, radiation treatment and hormonal therapy but remains incurable.

The individual endorses screening for those who are at higher risk.

"That is essential to me because of my children – they are in their late thirties and early forties – I want them tested as soon as possible. If I had been examined at 50 I am sure I would not be in the position I am currently," he said.

Future Steps

The National Screening Committee will have to weigh up the data and viewpoints.

While the new report says the ramifications for workforce and availability of a testing initiative would be manageable, opposing voices have argued that it would take diagnostic capabilities otherwise allocated to patients being cared for for different health issues.

The current discussion underscores the multifaceted trade-off between early detection and likely excessive intervention in prostate cancer management.